Crispr Theraptc (CRSP) Releases Earnings Results, Misses Expectations By $0.02 EPS
Crispr Theraptc (NASDAQ:CRSP) posted its earnings results on Wednesday. The company reported ($0.62) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02), Briefing.com reports. The firm had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($2.77) earnings per share.
Shares of Crispr Theraptc (CRSP) traded down $0.99 on Thursday, reaching $16.95. 348,021 shares of the company’s stock traded hands, compared to its average volume of 204,754. Crispr Theraptc has a twelve month low of $11.63 and a twelve month high of $25.00.
A number of analysts have recently weighed in on CRSP shares. Cann started coverage on shares of Crispr Theraptc in a report on Monday, July 17th. They set a “market perform” rating for the company. Barclays PLC restated a “buy” rating and issued a $29.00 price objective on shares of Crispr Theraptc in a report on Friday, September 8th. SunTrust Banks, Inc. started coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a report on Tuesday, July 18th. Finally, Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a report on Monday, August 14th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Crispr Theraptc has an average rating of “Buy” and an average price target of $23.08.
In related news, insider Samarth Kulkarni sold 27,154 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $20.08, for a total transaction of $545,252.32. Following the completion of the sale, the insider now owns 110,893 shares of the company’s stock, valued at $2,226,731.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kurt Von Emster sold 3,150 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $18.52, for a total transaction of $58,338.00. The disclosure for this sale can be found here. Insiders sold 343,060 shares of company stock valued at $6,778,681 over the last 90 days. 39.98% of the stock is currently owned by company insiders.
An institutional investor recently bought a new position in Crispr Theraptc stock. Vanguard Group Inc. bought a new position in Crispr Theraptc (NASDAQ:CRSP) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 17,019 shares of the company’s stock, valued at approximately $273,000. Hedge funds and other institutional investors own 25.52% of the company’s stock.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related stocks with our FREE daily email newsletter.